Clinical Trial Search

Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants

Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants

Primary: Number of Subjects Who Failed Treatment — 2 Participants

Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants

Primary: Duration of Hospital Stay — 3.9; 2.1 days

Primary: Length of Stay in the Hospital — 38.7; 39.5 hours — p=<0.05

Primary: Change in Pulmonary Function, as Measured by Serial Forced Expiratory Volume in 1 Second (FEV1) on Spirometry — -0.04 Liter — p=0.2030

Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants

Primary: Mean Change in FEV1 (Liters) From Baseline to Week 48 — -0.096; -0.067 Liters — p=0.6639

Primary: Mean Change in FEV1 (L) From Baseline to Week 48 — -0.186; -0.090 liters — p=0.7310

Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08

Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6

Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001

Primary: Number Of Participants With Chronic Rejection Who Met Primary Combined End-point — 2; 5 Participants — p=0.03

Primary: Count of Patients With Grade 3 or Higher Adverse Events. — 3 Participants